Nonclonal chromosomal aberrations induced by anti-tumoral regimens in childhood cancer: relationship with cancer-related genes and fragile sites.
Cytogenetic studies were performed on 80 pediatric cancer patients to observe the chromosomal damage, both quantitative and qualitative, induced by chemotherapy. Peripheral blood lymphocytes (PBL) (n = 127) were obtained at diagnosis, during treatment, at remission, and at relapse, and chromosome analysis performed utilizing G-banding standard procedures. The results show a significant increase in the number of altered karyotypes (P = 0.03) in the samples during treatment, returning to values that were similar to those at diagnosis at 2-year remission. Most of the chromosomal aberrations (CA) detected during the chemotherapy regimens were nonclonal, unbalanced (75%), and involved chromosomes 1, 3, 5, 6, 11, 12, 16, and 17 most frequently. There was also a marked increase of CA in samples at relapse with very similar features (type and distribution) to those detected during treatment. There was a good correlation between the chromosomal breakpoints in our series and fragile sites (58%), oncogene (75%), and tumor suppressor gene (33%) loci described in the literature. The results obtained suggest that cytostatic drugs induce a transient increase in chromosome fragility occurring at several cancer-associated breakpoints.
López de Mesa
R
R
Laboratory of Pediatrics, Department of Pediatrics, University of Navarra, Pamplona, Spain.
Sierrasesúmaga
L
L
Calasanz
M J
MJ
López de Cerain
A L
AL
Patiño-García
A
A
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D002648:Child; D002869:Chromosome Aberrations; D019457:Chromosome Breakage; D043283:Chromosome Fragile Sites; D002873:Chromosome Fragility; D006801:Humans; D007621:Karyotyping; D008214:Lymphocytes / Q000187:drug effects / Q000648:ultrastructure; D008223:Lymphoma / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D012516:Osteosarcoma / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D012512:Sarcoma, Ewing / Q000097:blood / Q000188:drug therapy / Q000235:genetics*
D000970:Antineoplastic Agents